ArticleAnnals of medicine and surgery (2012)2022
One year follow-up of intravitreal bevacizumab injection in Aggressive Retinopathy of Prematurity at Indonesian national referral hospital: Case series.
Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report the outcomes of children treated with intravitreal Bevacizumab (IVB) for Aggressive Retinopathy of Prematurity (A-ROP) at an Indonesian national referral hospital. Methods: This retrospective case series was conducted on all A-ROP patients who underwent IVB injection at a referral hospital in Indonesia in 2017-2020. Primary outcomes included regression, subsequent procedure, refractive error, and side effects. Results: Four patients (seven eyes) were included, with mean gestational age 29.8 weeks. Mean postmenstrual age at injection was 35 weeks. Mean duration from IVB injection to laser photocoagulation was nine days. ROP had regressed in all patients at one-year follow up after injection, and patients presented no systemic side effects. Conclusion: Use of IVB injection in A-ROP patients could be beneficial to prevent disease progression, and concomitant laser treatment can lead to better outcome. Prospective, larger sample size studies with long-term follow-up is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.